Stiripentol highlights the suitability of a small molecule LDHA inhibitor for PH1 treatment [53,57], after it was noticed that patients receiving stiripentol had a lower urine oxalate excretion. The gene discussed is LDHA; the disease is primary hyperoxaluria type 1.